Published in Clin Pharmacol Ther on November 09, 2016
The transformation in biomarker detection and management of drug-induced liver injury. Liver Int (2017) 0.75
"Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. Int J Mol Sci (2017) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol (2012) 3.15
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet (2010) 2.68
The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest (2012) 2.65
Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol (2006) 2.59
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut (1997) 2.35
Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol (2007) 2.18
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J (2007) 2.17
Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf (2006) 2.01
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol (2011) 1.60
Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther (2014) 1.52
Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol (2015) 1.49
The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett (2009) 1.42
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology (2014) 1.31
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant (2009) 1.21
Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev (2016) 1.15
Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev (2013) 1.12
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci (2013) 1.11
Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology (2013) 1.10
Acute liver failure including acetaminophen overdose. Med Clin North Am (2008) 1.10
Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol (2015) 1.03
Drug-induced acute liver failure. Clin Liver Dis (2013) 1.03
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf (2015) 1.02
Acetaminophen-induced Liver Injury: from Animal Models to Humans. J Clin Transl Hepatol (2014) 1.01
Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther (2011) 1.01
Circulating microRNAs: emerging biomarkers of liver disease. Semin Liver Dis (2015) 1.00
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology (2014) 0.99
Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis (2014) 0.95
Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes. Toxicol Appl Pharmacol (2012) 0.93
Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol In Vitro (2013) 0.92
The danger hypothesis applied to idiosyncratic drug reactions. Handb Exp Pharmacol (2010) 0.89
Naphthylisothiocyanate disposition in bile and its relationship to liver glutathione and toxicity. Biochem Pharmacol (1995) 0.89
Bile acids in drug induced liver injury: Key players and surrogate markers. Clin Res Hepatol Gastroenterol (2016) 0.89
Magnetic resonance enterography in pregnant women with Crohn's disease: case series and literature review. BMC Gastroenterol (2014) 0.88
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
Epigenetic profiles as defined signatures of xenobiotic exposure. Mutat Res Genet Toxicol Environ Mutagen (2013) 0.88
The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin Allergy (1982) 0.87
Development of novel tools for the in vitro investigation of drug-induced liver injury. Expert Opin Drug Metab Toxicol (2015) 0.85
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One (2013) 0.84
Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology (2015) 0.83
Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol (2016) 0.83
The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. Hum Exp Toxicol (2015) 0.83
Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis (2014) 0.83
Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opin Drug Metab Toxicol (2014) 0.82
The Multiple Facets of ABCB4 (MDR3) Deficiency. Curr Treat Options Gastroenterol (2007) 0.80
Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci (2013) 0.79
Modeling hepatitis B virus infection, immunopathology and therapy in mice. Antiviral Res (2015) 0.79
Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury? Toxicol Sci (2016) 0.79
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics (2016) 0.79
Mechanism of cell death in acute-on-chronic liver failure: a clinico-pathologic-biomarker study. Liver Int (2015) 0.78
A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. Hepatology (2016) 0.78
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicol Sci (2016) 0.78
Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury. Chem Res Toxicol (2015) 0.77
The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury. Chem Res Toxicol (2015) 0.77
Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model. Toxicol Sci (2015) 0.77
Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol (2014) 0.77
Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther (2016) 0.77
Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol (2015) 0.77
Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases. Toxicol Sci (2015) 0.77
Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach. Toxicol Sci (2017) 0.77
Prediction of the Clinical Risk of Drug-Induced Cholestatic Liver Injury Using an In Vitro Sandwich Cultured Hepatocyte Assay. Drug Metab Dispos (2015) 0.77
Inhibition of bile canalicular network formation in rat sandwich cultured hepatocytes by drugs associated with risk of severe liver injury. Toxicol In Vitro (2016) 0.76
Causal assessment of pharmaceutical treatments: why standards of evidence should not be the same for benefits and harms? Drug Saf (2015) 0.76
How to Diagnose and Exclude Drug-Induced Liver Injury. Dig Dis (2015) 0.76
Managing the risk of drug-induced liver injury. Clin Pharmacol Ther (2013) 0.76
Mitochondrial toxicity assessment in industry--a decade of technology development and insight. Expert Opin Drug Metab Toxicol (2014) 0.75